The emerging field of non-invasive brain stimulation in Alzheimer's disease
- PMID: 39562009
- PMCID: PMC11734340
- DOI: 10.1093/brain/awae292
The emerging field of non-invasive brain stimulation in Alzheimer's disease
Abstract
Treating cognitive impairment is a holy grail of modern clinical neuroscience. In the past few years, non-invasive brain stimulation is increasingly emerging as a therapeutic approach to ameliorate performance in patients with cognitive impairment and as an augmentation approach in persons whose cognitive performance is within normal limits. In patients with Alzheimer's disease, better understanding of brain connectivity and function has allowed for the development of different non-invasive brain stimulation protocols. Recent studies have shown that transcranial stimulation methods enhancing brain plasticity with several modalities have beneficial effects on cognitive functions. Amelioration has been shown in preclinical studies on behaviour of transgenic mouse models for Alzheimer's pathology and in clinical studies with variable severity of cognitive impairment. While the field is still grappling with issues related to the standardization of target population, frequency, intensity, treatment duration and stimulated region, positive outcomes have been reported on cognitive functions and on markers of brain pathology. Here we review the most encouraging protocols based on repetitive transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, visual-auditory stimulation, photobiomodulation and transcranial focused ultrasound, which have demonstrated efficacy to enhance cognitive functions or slow cognitive decline in patients with Alzheimer's disease. Beneficial non-invasive brain stimulation effects on cognitive functions are associated with the modulation of specific brain networks. The most promising results have been obtained targeting key hubs of higher-level cognitive networks, such as the frontal-parietal network and the default mode network. The personalization of stimulation parameters according to individual brain features sheds new light on optimizing non-invasive brain stimulation protocols for future applications.
Keywords: Alzheimer’s disease; photobiomodulation; transcranial alternating current stimulation; transcranial direct current stimulation; transcranial focused ultrasound; transcranial magnetic stimulation.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.
Conflict of interest statement
G.K. has received funding (competitive grants) not related to the current manuscript from the Alzheimer Drug Discovery Foundation (ADDF), European Commission Horizon 2020, Italian Ministry of Health, Italian Ministry of Education (MIUR), Brightfocus Foundation. G.K. also received funding from PIAM farmaceutici Spa and Epitech Group. G.K. is scientific co-founder and holds stocks of Sinaptica Therapeutics. G.K. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Epitech, Roche, Novo Nordisk. G.K. has the following patent issued: Combination drug formulations including rotigotine and an acetylcholinesterase inhibitor for the treatment of neurodegenerative diseases (n. 20230381512); Systems and methods for providing personalized targeted non-invasive stimulation to a brain network (n. 11998740). D.A. has received funding not related to the current manuscript through Swiss National Science Foundation and received a prize from Fondation Recherche Alzheimer. A.B. has received funding not related to the current manuscript through Fondation Recherche Alzheimer—SCOR, Fondazione Cariplo Airalzh, served as DSMB Chairman for the project Non-invasive Brain Stimulation for Gamma-induction and Cognitive Enhancement in FTD (Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA). Patents issued: Method of generating a diagnostic index for Alzheimer’s disease, electronic apparatus for implementing the method and system (n. 102016000110051); Nontherapeutic method of stimulation with gamma-tACS (n. 102021000000776). L.B. has received funding not related to the current manuscript through Swiss National Science Foundation. E.P.C. has received funding from the Italian Ministry of University and Research under the National Recovery and Resilience Plan (Fondi DM 502/2022—PNRR MC42 Bando Giovani Ricercatori). E.S. has received funding not related to the current manuscript from National Institutes of Health (NIH), Alzheimer Drug Discovery Foundation (ADDF). E.S. is scientific co-founder and holds stocks of Sinaptica Therapeutics. E.S. has a patent issued on Systems and methods for providing personalized targeted non-invasive stimulation to a brain network (n. 11998740). G.B.F. has received funding not related to the current manuscript through the Private Foundation of Geneva University Hospitals from: A.P.R.A.—Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Race Against Dementia Foundation, London, UK; Fondation Child Care, Genève; Fondation Edmond J. Safra, Genève; Fondation Minkoff, Genève; Fondazione Agusta, Lugano; McCall Macbain Foundation, Canada; Nicole et René Keller, Genève; Fondation AETAS, Genève. He has received funding through the University of Geneva or Geneva University Hospitals: for IISSs from ROCHE Pharmaceuticals OM Pharma EISAI Pharmaceuticals Biogen Pharmaceuticals and Novo Nordisk; for competitive research projects from: H2020, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, and VELUX Foundation. G.B.F. has received consulting fees from: Biogen, Diadem, Roche. All to his institution. G.B.F. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Biogen, Roche, Novo Nordisk, GE HealthCare. All to his institution.
Figures
References
-
- Frisoni GB, Molinuevo JL, Altomare D, et al. . Precision prevention of Alzheimer’s and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimers Dement. 2020;16:1457–1468. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
